DOCSLIB.ORG

Algorithms for Molecular Testing in Solid Tumours

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Algorithms for Molecular Testing in Solid Tumours 286 Algorithms for molecular testing in solid tumours A. Hébrant, Ir, PhD1, M. Lammens, MD, PhD2, C. Van den Broecke, MD3, N. D’Haene, MD, PhD4, J. Van den Oord, MD, PhD5, A. Vanderstichele, MD, PhD6, A. Dendooven, MD, PhD7,8, P. Neven, MD, PhD6,9, K. Punie, MD, PhD10, G. Floris, MD, PhD7,11,12, J. Van der Meulen, Ir, PhD13, HA. Poirel, MD, PhD14, C. Dooms, MD, PhD15, S. Rottey, MD, PhD16, T. Boterberg, MD, PhD17, L. Brochez, MD, PhD18, MC. Burlacu, MD19, G. Costante, MD20, D. Creytens, MD, PhD8,21, P. De Paepe, MD, PhD22, R. De Pauwn, MD23, B. Decallonne, MD, PhD24, F. Dedeurwaerdere, MD25, H. Denys, MD, PhD16, L. Ferdinande, MD, PhD8,21, R. Forsyth, MD, PhD26, M. Garmyn, MD, PhD27, T. Gevaert, MD, PhD28,29, J. De Greve, MD, PhD30, E. Govaerts, MD31, E. Hauben, MD, PhD5,11, J. Kerger, MD32, O. Kholmanskikh Van Criekingen, MD, PhD33, V. Kruse, MD, PhD16, Y. Lalami, MD32, L. Lapeire, MD, PhD16,21, P. Lefesvre, MD, PhD34, JP. Machiels, MD, PhD35, B. Maes, MD, PhD36, G. Martens, MD, PhD37, M. Remmelink, MD, PhD4, I. Salmon, MD, PhD4, R. Sciot, MD, PhD11, S. Tejpar, MD, PhD38, K. Van de Vijver, MD, PhD8,21, L. Van de Voorde, MD39, I. Van den Berghe, MD22, A. Van den Bruel, MD40, K. Vandecasteele, MD, PhD17,21, L. Vanwalleghem, MD22, K. Vermaelen, MD, PhD41, R. Salgado, MD, PhD42, E. Wauters, MD, PhD15, B. Weynand, MD, PhD5, E. Van Valckenborgh, PhD1, G. Raicevic, PhD1, M. Van den Bulcke, PhD1, P. Pauwels, MD, PhD2 1Cancer Centre, Sciensano, Brussels, 2Department of Pathology, Antwerp University Hospital, and Centre for Oncological Research (CORE), University of Antwerp, Antwerp, 3Department of Pathology, AZ Sint-Lucas Ghent, Ghent, 4Department of Pathology, Hôpital Erasme - Université Libre de Bruxelles (ULB), Brussels, 5Department of Pathology, KU Leuven- University Hospitals Leuven, Leuven, Belgium, 6Department of Oncology, KU Leuven, Leuven, 7Department of Pathology, UZ Antwerp; MIPRO/LEMP, University of Antwerp, Antwerp, 8Department of Pathology, UZ Gent, Ghent, 9Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, 10Department of General Medical Oncology. University Hospitals Leuven, 11Department of Imaging and Pathology, KU Leuven- University of Leuven, Leuven, 12Laboratory of Translational Cell & Tissue Research, Leuven, 13Molecular Diagnostics Ghent University Hospital (MDG), Ghent University Hospital, Ghent, 14Belgian Cancer Registry, Brussels, 15Department of Respiratory Diseases and Respiratory Oncology Unit, KU Leuven, Leuven, 16Department of Medical Oncology, Ghent University Hospital, Ghent, 17Department of Radiation Oncology, Ghent University Hospital, Ghent, 18Dermatology University Hospital Ghent, Cancer Research Institute Ghent (CRIG), Ghent, 19Department of Endocrinology, Cliniques Universitaires St-Luc, Brussels, 20Endocrinology Clinic, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, 21Cancer Research Institute Ghent (CRIG), Ghent University, Ghent, 22Department of Pathology, AZ Sint-Jan Brugge-Oostende, 23Department of Pulmonology, AZ Sint-Jan Brugge-Oostende, 24Department of Endocrinology, University Hospitals Leuven, 25Department of Pathology, AZ Delta, Roeselare, 26Department of Pathology, University Hospital Brussels and Experimental Pathology, Vrije Universiteit Brussel, Brussels, 27Department of Dermatology, University Hospitals Leuven, Leuven, 28Organs Systems, KU Leuven, Leuven, 29Department of Pathology, AZ Klina, Brasschaat, 30Department of Medical Oncology, Oncologisch Centrum, UZ Brussel, Vrije Universiteit Brussel, Brussels, 31Department of pneumology, AZ Sint-Lucas Hospital, Ghent, 32Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, 33Federal Agency for Medicines and Health Products, Brussels, 34Department of Anatomic Pathology, UZ Brussel, Brussels, 35Department of medical oncology, Cliniques universitaires Saint-Luc, Brussels, 36Department of Clinical Biology, Jessa Hospital, Hasselt, 37Department of Laboratory Medicine, AZ Delta, Roeselare, 38Molecular Digestive Oncology, Kuleuven, Leuven, 39Department of Radiation Oncology, AZ Sint-Lucas, Ghent, 40Department of Internal Medicine, Endocrinology, AZ Sint Jan Brugge- Oostende, 41Departement of Pulmonary Medicine, Ghent University Hospital, Ghent, 42Department of Pathology GZA-ZNA, Antwerp. Please send all correspondence to: A. Hébrant, Ir, PhD, Rue Juliette Wytsman 14, 1050 Brussels, Belgium, tel: +32 2 642 57 32, email: aline. [email protected]. Conflict of interest: K. Punie declares to receive honoraria for consulting/advisory from Astra Zeneca, Novartis, Pfizer, Roche and Vifor Pharma as well as speaker fees from Novartis and Pfizer. Honoraria and fees were paid to the institution. Keywords: brain cancer, endometrium cancer, head and neck cancer, lung cancer, melanoma, molecular tests, NGS, oncology, ovarian cancer, soft tissue tumours, thyroid tumours. Acknowledgements: The authors would like to acknowledge all the ComPerMed experts. VOLUME13NOVEMBER2019 PRACTICE GUIDELINES 287 SUMMARY In order to advise the Federal Government on the reimbursement of molecular tests related to Personalised Medicine in Oncology, the Commission of Personalised Medicine (ComPerMed), represented by Belgian experts, has developed a methodology to classify molecular testing in oncology. The different molecular tests per cancer type are represented in algorithms and are annotated with a test level reflecting their rele- vance based on current guidelines, drug approvals and clinical data. The molecular tests are documented with recent literature, guidelines and a brief technical description. This methodology was applied on different solid tumours for which molecular testing is a clear clinical need. (BELG J MED ONCOL 2019;13(7):286-95) INTRODUCTION type, the corresponding working group of the ComPerMed The clinical management of patients with cancer has become (Table 1) started with a systematic evaluation of all molecular more challenging with the advent of numerous innovative tests currently performed in clinical routine in Belgium, tak- molecular tests giving the opportunity to the care givers to ing into account their test utility (diagnostic, prognostic or tailor the patient’s management by fine-tuning the diagno- therapeutic), and then assigned, for each of them, a test lev- sis or by predicting the resistance or response to a thera- el. Three test levels (Table 2) were defined, with level 1 rep- py. In addition, test results may also provide information resenting the highest priority of implementation of the test on prognosis. by the policy makers. These test levels are assigned based on In order to advise the Federal Government on the reimburse- their use in clinical guidelines, expert opinions and on reim- ment of molecular tests related to Personalised Medicine in bursement rules for drugs in Belgium. This test level scale al- Oncology, the Belgian Commission of Personalised Medi- lows easy implementation of common biomarker testing into cine (ComPerMed) was created in 2016. This commission clinical practice. Furthermore, it facilitates the development includes representatives of all professional organisations di- of reimbursement criteria. rectly involved in personalised medicine, including experts In this paper, the methodology has been applied for lung, from the College of Genetics, the College of Oncology, the melanoma, brain, endometrium, ovarian, head and neck, soft Commission of Anatomic Pathology, the Commission of tissue, and thyroid tumours. Clinical Biology and different working groups with Belgian oncologists, haematologists, pathologists, clinical biologists, ALGORITHMS geneticists and other scientists. The ComPerMed is organised To design the molecular test algorithms, only tests with a lev- in different working groups according to the tumour type. el of 1 or 2A were retained. However, some tests with level 2B The ComPerMed advises the Platform Companion Diagnos- were also added to the algorithm if the expert group estimat- tics (CDx platform) from the Belgian reimbursement agency ed that they will become a test level 1 or 2A in the near future. National Institute for Health and Disability Insurance (NIH- For lung, melanoma, brain, endometrium, ovarian, head and DI) or RIZIV/INAMI on decision making related to the reim- neck, soft tissue and thyroid tumours, the different molecu- bursement of diagnostic tests in personalised medicine. The lar tests used in Belgium are sequentially represented in the CDx platform, launched in January 2016, aims to evaluate shape of algorithms (Figures 1-8). These algorithms are pub- the reimbursement of a molecular test and the correspond- lished on the ComPerMed website www.compermed.be/ with ing patient management in personalised medicine. additional information, such as tumour incidence (provid- The ComPerMed has set up a methodology in order to sys- ed by the Belgian Cancer Registry), and, for each molecular tematically evaluate and prioritise, for different tumour types, test, its utility (diagnostic, prognostic or therapeutic utility), the molecular tests currently performed in Belgium in clini- its corresponding test level and a brief technical test descrip- cal routine or in research phase.1 tion. In case of next generation sequencing (NGS) testing, the genes and regions that have to be analysed at minimum are METHODOLOGY also described. These algorithms will be reviewed annual- The methodology has been previously described and applied ly. Additional updates of the gene tests are possible when re- for digestive and breast
Load more

Recommended publications
  • SARS-Cov-2 Prevalence and Seroprevalence Among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.10.03.20204545; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title: SARS-CoV-2 Prevalence and Seroprevalence among Healthcare Workers in Belgian Hospitals: Baseline Results of a Prospective Cohort Study Authors*: Laure Mortgat1,2, MD Cyril Barbezange3, PhD Natalie Fischer3,4, PhD Leo Heyndrickx5, MSc Veronik Hutse3, PhD Isabelle Thomas3, PhD Bea Vuylsteke6, PhD Kevin Arien5,7,8, PhD Isabelle Desombere3,8, PhD Els Duysburgh1,8, PhD Affiliations: 1. Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium 2. European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 3. Department of Infectious diseases in humans, Sciensano, Brussels, Belgium 4. European Public Health Microbiology Training (EUPHEM), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 5. Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium 6. Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium 7. University of Antwerp 8. Equal contributions as last author *alphabetical order for middle authors Corresponding author: Laure Mortgat, Rue Juliette Wytsman 14, 1050 Brussels, BelgiumNOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. [email protected], + 32 2 642 57 42 medRxiv preprint doi: https://doi.org/10.1101/2020.10.03.20204545; this version posted October 6, 2020.
    [Show full text]
  • List of Participants
    List of participants GHS Heads of delegation 2015 Start Date: End Date: Participants: 77 Governments (ECOSOC Bodies) - Member States of the Body Argentina Mr. GUSTAVO ALBORNOZ Avenida Eduardo Madero Nº 235 1106 Buenos Aires Dangerous Goods Division Cheif Argentina PREFECTURA NAVAL ARGENTINA (ARGENTINE COAST GUARD) Phone: +541143187664 Fax: +541143187666 Email: [email protected] Australia Mrs. Julia COLLINS GPO Box 641 Branch Manager ACT 2601 WHS Framework Branch Australia Safe Work Australia Phone: + 61 2 62409238 Email: [email protected] Austria Mr. Hermann GÖTSCH Stubenring 1 A-1010 Vienna Civil Servant, Legal Adviser Austria Federal Ministry for Agriculture, Forestry, Environment and Water Management, Austria Phone: 00 43 1 71100 6874 Fax: 00 431 513 1679-1089 Email: [email protected] Website: www.lebensministerium.at Belgium Ms. Marie-Noëlle BLAUDE Juliette Wytsman 14 B-1050 Regulatory toxicologist Belgium Scientific Institute of Public Health Phone: +32 2 642 55 87 Fax: +32 2 642 52 24 Email: [email protected] Brazil Mr. Roque PUIATTI Avenue Lucas de Oliveira 337 ap 203 Health and Safety Inspect 90440-011 RS PORTO ALEGRE Ministry of Labour and Employment Brazil Phone: 00 55 5 133 88 1036 Fax: 00 55 5 133 88 1036 Email: [email protected] 1 Thursday, July 17, 2014 GHS Heads of delegation 2014 Governments (ECOSOC Bodies) - Member States of the Body Canada Ms. Amira SULTAN 269 Laurier Avenue West K1A 0K9 Ottawa Supervisor, Regulatory Policy and Risk Management Canada Policy and Program Development Bureau Health Canada Phone: 613-948-2042 Email: [email protected] China Mr.
    [Show full text]
  • Health Expectancy by Socio-Economic Status in Belgium
    Health Expectancy by socio-economic status in Belgium Bossuyt N., Van Oyen H. Scientific Institute of Public Health Unit of Epidemiology Rue Juliette Wytsman 14 B-1050 Brussels ( 32 2 642 57 40 fax. 32 2 642 54 10 email: [email protected] http://www.iph.fgov.be/epidemio/ I Table of contents Table of contents II Table of tables IV Table of figures IX Summary X 1. Introduction 1 1. Socio-economic differences in health 2 1.1 Indications of socio-economic differences in health 2 1.2 Explanatory mechanisms for socio-economic differences in health 3 1.3 Points of action for intervention 5 1.4 Development of the health of a population 5 1.4.1 Epidemiologic transition 5 1.4.2 Ageing 6 1.4.3 Recent developments in health indicators 7 2. Material and methods 10 2.1 Calculation method 10 2.1.1 Methods for calculating health expectancy 10 2.1.2 Practical application of the Sullivan method 10 2.1.3 Age groups 15 2.2 Figures 16 2.2.1 Breakdown of the mortality and morbidity data according to socio-economic status 16 2.2.2 Mortality data of this study 18 2.2.3 Morbidity data in this study 18 2.3 Selection of indicators 22 2.3.1 Indicators of socio-economic status 22 2.3.2 Indicators of state of health 24 2.4 Measuring differences 26 2.5 Conversion from absolute to relative socio-economic status 27 3. Results 30 3.1 Life expectancy according to sex and education level 30 3.2 Prevalences according to education level 31 3.3 Life expectancy in good perceived health 34 3.3.1 Life expectancy in good perceived health according to sex 34 3.3.2 Life
    [Show full text]
  • List of Participants
    Lepr Rev (1992) 63, Supplement, 124s-126s List of Participants Dr A S Abdullah, Medical Officer, Leprosy, WHO Regional Officefor South-East Asia, New Delhi, India Dr Wan Alkaradi, Sub-Directorate Leprosy Control, Directorate-General CDC & EH, Ministry of Health, Jalan Percetaken Negara No. 29, P.O. Box 223, Jakarta, 10560 Indonesia Dr (Mrs) Ngeri Benebo, National TB/Leprosy Control Programme, Federal Ministry of Health, Ikoyi, Lagos, Nigeria Dr L Blanc, Medecin-Epidemiologist-OCCGE, Institut Marchoux, B.P. 251, Bamako, Mali Dr V Cellona, Assistant Director, Leonard Wood Memorial, Centre for Leprosy Research, P.O. Box 727, Cebu City, Philippines Dr N Chitimba, Medical Officer, Leprosy, WHO Sub-Regional Office III, Harare, Zimbabwe Dr H J Chum, Ministry of Health, Samora Avenue, P.O. Box 9083, Dar es-Salaam, Tanzania Dr 0 Daumerie, Short-term Consultant, Leprosy Unit, WHO, Geneva, Switzerland Dr E Declercq, Institut d'Hygiene et d'Epidemiologie, Rue Juliette Wytsman 14, 1050 Brussels, Belgium Dr Djumhana, Ministry of Health, Jalan Percetaken Negara No. 29, P.O. Box 223, Jakarta, 10560 Indonesia Dr R Farrugia, Medical Officer, CHD, WHO Regional Office for Western Pacific, Manila, Philippines *Dr W Felton Ross, Medical Director, American Leprosy Missions, 1 ALM Way, Greenville, South Carolina 29601, USA Dr J Ferreira, Leprologist, Fundayao Servicios de Saude Publica, Caixa Postal 472, 90 000 Porto Alegre, Rio Grande Do Sui, Brazil Dr P Fine, London School of Hygiene and Tropical Medicine, Keppel Street, London WCIE 7HT, UK Dr M 0 Gupte, Project Officer, CJIL Field Unit for Epidemiology of Leprosy, Indian Council of Medical Research, 271 Nehru Bazaar, Avadi, Madras 600 054, India Dr J 0 F Habbema, Professor of Medical Decision Sciences, Department of Public Health and Social Medicine, Erasmus University Rotterdam, P.O.
    [Show full text]
  • The 100 Years of the Fungus Collection Mucl 1894-1994
    THE 100 YEARS OF THE FUNGUS COLLECTION MUCL 1894-1994 Fungal Taxonomy and Tropical Mycology: Quo vadis ? Taxonomy and Nomenclature of the Fungi Grégoire L. Hennebert Catholic University of Louvain, Belgium Notice of the editor This document is now published as an archive It is available on www.Mycotaxon.com It is also produced on CD and in few paperback copies G. L. Hennebert ed. Published by Mycotaxon, Ltd. Ithaca, New York, USA December 2010 ISBN 978-0-930845-18-6 (www pdf version) ISBN 978-0-930845-17-9 (paperback version) DOI 10.5248/2010MUCL.pdf 1894-1994 MUCL Centenary CONTENTS Lists of participants 8 Forword John Webser 13 PLENARY SESSION The 100 Year Fungus Culture Collection MUCL, June 29th, 1994 G.L. Hennebert, UCL Mycothèque de l'Université Catholique de Louvain (MUCL) 17 D. Hawksworth, IMI, U.K. Fungal genetic resource collections and biodiversity. 27 D. van der Mei, CBS, MINE, Netherlands The fungus culture collections in Europe. 34 J. De Brabandere, BCCM, Belgium The Belgian Coordinated Collections of Microorganisms. 40 Fungal Taxonomy and tropical Mycology G.L. Hennebert, UCL Introduction. Fungal taxonomy and tropical mycology: Quo vadis ? 41 C.P. Kurtzman, NRRL, USA Molecular taxonomy in the yeast fungi: present and future. 42 M. Blackwell, Louisiana State University, USA Phylogeny of filamentous fungi deduced from analysis of molecular characters: present and future. 52 J. Rammeloo, National Botanical Garden, Belgium Importance of morphological and anatomical characters in fungal taxonomy. 57 M.F. Roquebert, Natural History Museum, France Possible progress of modern morphological analysis in fungal taxonomy. 63 A.J.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2016-014094 on 17 February 2018. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay- per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 29, 2021 by guest. Protected copyright. BMJ Open: first published as 10.1136/bmjopen-2016-014094 on 17 February 2018. Downloaded from BMJ Open Predicting End of Work Disability After Cancer. A 7 years Follow-up Population-based Cohort Study Using Competing Risks Analysis For peer review only Journal: BMJ Open Manuscript ID bmjopen-2016-014094 Article Type: Research Date Submitted by the Author: 30-Aug-2016 Complete List of Authors:
    [Show full text]
  • Belgium to the Convention on Biological Diversity
    Fifth National Report of Belgium to the Convention on Biological Diversity (Th. Hubin, RBINS) 2014 2 Contents Executive Summary ..................................................................................................................................................... 4 Preamble ....................................................................................................................................................................... 6 Chapter I - Overview of Biodiversity Status, Trends and Threats .......................................................................... 7 1. Importance of biodiversity in Belgium .................................................................................................................. 7 2. Status of biodiversity ........................................................................................................................................... 10 3. Trends in biodiversity .......................................................................................................................................... 16 4. Main threats to biodiversity ................................................................................................................................. 29 Chapter II - Status of national biodiversity strategies and action plans, their implementation, and the mainstreaming of biodiversity .................................................................................................................................. 44 1. Introduction ........................................................................................................................................................
    [Show full text]
  • PDF Van Tekst
    Verzameld journalistiek werk. Deel 6. Nieuwe Rotterdamsche Courant januari 1913 - november 1913 Karel van de Woestijne Editie Ada Deprez bron Karel van de Woestijne, Verzameld journalistiek werk. Deel 6: Nieuwe Rotterdamsche Courant januari 1913 - november 1913 (ed. Ada Deprez). Cultureel Documentatiecentrum, Gent 1990 Zie voor verantwoording: http://www.dbnl.org/tekst/woes002verz17_01/colofon.php © 2010 dbnl / Ada Deprez 11 Van meet af Brussel, 15 Januari. ‘C'est ça, la politique?’ vroeg mij, nog geen zeven en vijftig minuten geleden het aanbiddelijke pruilmondje van de schoone, negentienjarige dochter van het Kamerlid (‘je ne saurais pour un empire vous la nommer’ zou Musset hebben gezegd), wier rozevingeren ik was gaan kussen in de ‘tribune de la questure’, aldaar ze voor 't eerst eene Kamerzitting had bijgewoond. ‘C'est ça, la politique?’ Onder ons gezeid en elders gezwegen, ik geloof wel dat de vader van het goddelijke kind (neem mij niet kwalijk, mevrouw!) met opzet dézen dag had gekozen, om aan zijne dochter voor goed den lust te benemen, nog ooit naar de Kamer te komen. Misschien heeft de man daar goede redenen voor.... De waarheid is, dat ik, in mijne lange carrière, geene zitting heb bijgewoond als deze van heden. De vacantie was uit. Na drie weken kwamen wij weêr bijeen. En wij deden het met ijver: wij hadden het immers, voor heden, en morgen, en overmorgen, en ik weet niet hoevele maanden nog, zoo druk! Daar was de militaire wet. Daar was de grondwetsherziening. Daar was.... ‘C'est ça, la politique?’ Waarlijk, ik bloosde bij de vraag uit het bovengemelde maar aanbiddelijke pruilmondje.
    [Show full text]
  • Pesticide Residues on Three Cut Flower Species and Potential Exposure of Florists in Belgium
    International Journal of Environmental Research and Public Health Article Pesticide Residues on Three Cut Flower Species and Potential Exposure of Florists in Belgium Khaoula Toumi 1,*, Christiane Vleminckx 2, Joris van Loco 2 and Bruno Schiffers 1 1 Gembloux Agro-Bio Tech/ULg—Laboratoire de Phytopharmacie, Passage des Déportés 2, Gembloux 5030, Belgium; [email protected] 2 Institut Scientifique de Santé Publique, OD Food, Medecines and Consumer Safety, Rue Juliette Wytsman 14, Brussels 1050, Belgium; [email protected] (C.V.); [email protected] (J.v.L.) * Correspondence: [email protected]; Tel.: +32-081-622-215 Academic Editor: Ricardo Bello-Mendoza Received: 11 July 2016; Accepted: 19 September 2016; Published: 23 September 2016 Abstract: In order to assess the prevalence of pesticide contamination and the risk of florists’ exposure when handling cut flowers, sampling and analysis of 90 bouquets of the most commonly sold cut flowers in Belgium (50 bouquets of roses; 20 of gerberas, and 20 of chrysanthemums) were carried out. The bouquets were collected from 50 florists located in the seven largest cities of Belgium (Antwerp, Brussels, Charleroi, Ghent, Leuven, Liege, and Namur) and from five supermarkets located in the different regions. To have a better understanding of the route of exposure and professional practices a questionnaire was also addressed to a group of 25 florists who volunteered to take part in the survey. All florists were interviewed individually when collecting the questionnaire. The residual pesticide deposit values on cut flowers were determined in an accredited laboratory using a multi-residue (QuEChERS Quick Easy Cheap Effective Rugged Safe) method and a combination of gas chromatography (GC) and liquid chormatograhphy (LC) analysis.
    [Show full text]
  • Media Pack 2019
    antiques trade THE A RT M AR KET W EEKLY antiquestradegazette.com Reach a unique audience of buyers, collectors and market professionals... Media Pack 2019 PRINT DIGITAL More than More than 25,000 readers 80,000 unique every week users a month ...and broaden your campaign to reach more than 1 million users a month on our sister site: thesaleroom.com The home of art & antiques auctions The authority of the art and antiques trade 1 antiques trade PRINT THE A RT M AR KET W EEKLY Welcome to Antiques Trade Gazette The Art Market Weekly Whether you buy, sell or merely ISSUE 2380 | antiquestradegazette.com | 23 February 2019 | UK £4.99 | USA $7.95 | Europe €5.50 Coins & Medals Annual in-depth antiques trade review of London’s observe and enjoy the art, antiques and numismatics auctions pages 14-20 vintage markets, Antiques Trade Gazette “Fantastic THE ART M ARKET WEEKLY is the must-read weekly newspaper. A Victorian who’s who publication by Frances Allitt Oscar Wilde is among the famous faces in this huge work on sale from a family collection for - the antiques the first time A 19th century masterpiece by William Powell Frith (1819- 1909) that serves as a who’s who of influential Victorians is on offer from a new St James’s gallery for £10m. The Private View at the Royal dealer’s bible” Academy, 1881, is the last of Frith’s great panoramas (which include The Derby Day and Rail- way Station) and comes fresh to the market after 135 years in the Every issue is packed with breaking news, exclusive same family collection.
    [Show full text]
  • 2003 Heat Wave
    V O L . 1 0 I s s u e s 7- 9 Jul-Sep 2005 EUROPEAN COMMUNICABLE DISEASE JOURNAL Euroroundup • Severe Streptococcus pyogenes associated disease in Europe 2003 Heat Wave O utbreak report • Outbreak of mumps in Sweden Outbreak dispatches • Salmonellosis outbreaks due to imported foods • S HORT REPORTS More hantavirus infections than usual in some European countries FUNDED BY DG HEALTH AND CONSUMER PROTECTION OF THE COMMISSION OF THE EUROPEAN COMMUNITIES "Neither the European Commission nor any person acting on the behalf of the Commission is responsible for the use which might be made of the information in this journal. The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Commission, the European Centre for Disease Prevention and Control ( ECDC ), the Institut de veille sanitaire ( InVS ), the Health Protection Agency ( HPA ) or the institutions with which the authors are affiliated" Eurosurveillance V O L . 1 0 I s s u e s 7- 9 Jul-Sep 2005 Peer-reviewed European information on communicable disease surveillance and control Articles published in Eurosurveillance are indexed by Medline/Index Medicus C ONTENTS E DITORIALS 1 4 6 • Production of Eurosurveillance to be shared with the ECDC 146 Editorial team • Vulnerable population: lessons learnt from the summer 2003 heat waves in Europe 147 G Brücker Editorial offices • The 2003 European heat waves 148 France T Kosatsky Institut de Veille Sanitaire (InVS) 12, rue du Val d’Osne 94415 Saint-Maurice, France O RIGINAL ARTICLES
    [Show full text]
  • Be Heritage Be . Brussels
    HISTORY HERITAGE DAYS AND MEMORY 20 & 21 SEPT. 2014 be heritage be . brussels Info Featured pictograms Organisation of Heritage Days in Brussels-Capital Region: Regional Public Service of Brussels/Brussels Urban Development Opening hours and dates Department of Monuments and Sites a CCN – Rue du Progrès/Vooruitgangsstraat 80 – 1035 BRUSSELS Telephone helpline open on 20 and 21 September from 10h00 to 17h00: M Metro lines and stops 02/204.17.69 – Fax: 02/204.15.22 – www.heritagedaysbrussels.be [email protected] – #jdpomd – Bruxelles Patrimoines – Erfgoed Brussel T Trams The times given for buildings are opening and closing times. In case of large crowds, the organisers reserve the right to close the doors earlier in order to finish at the foreseen time. B Bus Smoking, eating and drinking is prohitited and in certain buildings the taking of photographs is not allowed either. Walking Tour/Activity “Listed” at the end of notices indicates the date on which the property described g was listed or registered on the list of protected buildings. The coordinates indicated at the top in color refer to a map of the Region. h Exhibition/Conference A free copy of this map can be requested by writing to the Department of Monuments and Sites. Bicycle Tour Information relating to public transport serving the sites was provided by STIB. b It indicates the closest stops to the sites or starting points and the lines served on Saturdays and Sundays. Music Please note that advance bookings are essential for certain tours (reservation ♬ number indicated below the notice). This measure has been implemented for the sole purpose of accommodating the public under the best possible conditions i Guided tour only or and ensuring that there are sufficient guides available.
    [Show full text]